|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
2
|
|
gptkbp:bfsParent
|
gptkb:physicist
|
|
gptkbp:acquisition
|
gptkb:Affinivax
gptkb:Galvani_Bioelectronics
gptkb:Pionyr_Immunotherapeutics
gptkb:Zymeworks
gptkb:Tetra_Logic_Pharmaceuticals
gptkb:Immunocore
gptkb:Zynerba_Pharmaceuticals
gptkb:Sierra_Oncology
gptkb:Synthego
gptkb:Stiefel_Laboratories
gptkb:Cure_Vac
gptkb:Alder_Bio_Pharmaceuticals
gptkb:Tesaro
gptkb:Smith_Kline_Beecham
Biontech.
Bristol-Myers Squibb's consumer health business
|
|
gptkbp:ceo
|
gptkb:Emma_Walmsley
|
|
gptkbp:clinical_trial
|
gptkb:drug
shingles vaccine
influenza vaccine
malaria vaccine
|
|
gptkbp:competitors
|
gptkb:temple
gptkb:Johnson_&_Johnson
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Novartis
|
|
gptkbp:employees
|
99,000 (2020)
|
|
gptkbp:formed
|
merger of Glaxo Wellcome and Smith Kline Beecham
|
|
gptkbp:founded
|
gptkb:2000
|
|
gptkbp:headquarters
|
gptkb:Brentford,_England
Brentford, London, England
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Glaxo Smith Kline
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:key_people
|
gptkb:Professor_Sir_Andrew_Witty
gptkb:Emma_Walmsley
|
|
gptkbp:notable_products
|
gptkb:Zyban
gptkb:Shingrix
gptkb:Breztri_Aerosphere
gptkb:Wellbutrin
gptkb:Tafinlar
gptkb:Zantac
gptkb:Bexsero
gptkb:Nexium
gptkb:Advair
gptkb:Augmentin
gptkb:Avodart
gptkb:Fluarix
gptkb:Seretide
gptkb:Trelegy_Ellipta
gptkb:Dulera
gptkb:Paxil
Lamictal
|
|
gptkbp:operates_in
|
global market
|
|
gptkbp:parent_company
|
gptkb:Glaxo_Smith_Kline_plc
|
|
gptkbp:partnership
|
gptkb:temple
gptkb:Sanofi
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Regeneron
gptkb:Novartis
|
|
gptkbp:philanthropy
|
GSKIMPACT Awards
GSK's Global Health Programs
|
|
gptkbp:products
|
gptkb:drug
antibiotics
vaccines
antidepressants
prescription medicines
consumer healthcare products
|
|
gptkbp:research
|
gptkb:Dr._Hal_Barron
oncology
infectious diseases
immunology
respiratory diseases
|
|
gptkbp:research_focus
|
oncology
vaccines
infectious diseases
immunology
respiratory diseases
|
|
gptkbp:revenue
|
£34.1 billion (2020)
£34 billion (2020)
|
|
gptkbp:stock_exchange
|
gptkb:London_Stock_Exchange
|
|
gptkbp:subsidiary
|
gptkb:Vii_V_Healthcare
gptkb:Consumer_Healthcare
gptkb:Stiefel_Laboratories
HIV medicines
HIV therapeutics
|
|
gptkbp:sustainability
|
community engagement
environmental initiatives
diversity and inclusion initiatives
community investment
healthcare access initiatives
access to medicines
|
|
gptkbp:symbol
|
gptkb:GSK
|
|
gptkbp:website
|
www.gsk.com
|